Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Nephrology

Living with Glaudemans Type: Long-Term Outlook

At a Glance

Glaudemans type hypomagnesemia requires lifelong, individualized monitoring because magnesium levels can fall dangerously during illness and affect heart rhythm or the nervous system. Regular electrolyte and kidney checks, appropriate EKGs, and a sick-day plan help manage risk.

Living with Isolated Autosomal Dominant Hypomagnesemia (Glaudemans Type) means managing a condition that is often “invisible” to others but requires consistent, lifelong attention. Because this condition is so rare, there are no large-scale studies on long-term outcomes, and survival data is incompletely known [1][2].

Your Long-Term Outlook

While data is limited due to the small number of people diagnosed worldwide, the long-term outlook depends on your specific genetic variant, your kidney function, and how well severe electrolyte complications are controlled.

  • Life Expectancy: The limited published experience has not established a clear signal of shortened survival for the renal hypomagnesemia phenotype, but it cannot establish a guaranteed life expectancy or entirely exclude the risk of rare, serious complications like arrhythmias or seizures [2][3].
  • Kidney Health: Unlike some other genetic magnesium disorders, Glaudemans Type is not typically associated with widespread nephrocalcinosis (calcium deposits in the kidney) [1]. However, your doctors will still monitor your kidney function (eGFR) as part of your routine care to ensure your kidneys remain healthy as you age [4][5].

Routine Monitoring Schedule

Because your body is constantly losing magnesium, “set-it-and-forget-it” treatment rarely works. Most specialists recommend a proactive monitoring schedule, though these intervals are just examples and should be individualized based on your symptoms, treatment, kidney function, and any intercurrent illnesses or pregnancies [2][5].

  • Electrolyte Panels (e.g., Every 3–6 Months): Periodic checks of your magnesium, calcium, and potassium. These levels can shift based on your diet, hydration, and stress levels [2][6].
  • Kidney Function (e.g., Annually): Blood tests for creatinine and eGFR to ensure your kidneys are filtering effectively [4].
  • Cardiac Monitoring (Baseline and Periodic): An EKG (electrocardiogram) to check your QTc interval. Very low magnesium can sometimes cause “electrical delays” in the heart, making you more susceptible to arrhythmias [7][8].
  • Neurological Evaluation: Periodic check-ins with a neurologist can help track any twitching (myokymia) or balance issues that may occur independently of your magnesium levels [9][10].

Managing the “Invisible” Burden

The psychological toll of a rare disease can be significant. Patients with similar rare electrolyte disorders often score lower on quality-of-life surveys, citing fatigue and “brain fog” as major daily hurdles [11][12].

  • Triggers to Avoid: Many patients find that physical or emotional stress, fever, and fatigue can potentially trigger their symptoms [13][14]. Alcohol can contribute to magnesium loss, so you should discuss practical guidelines with your doctor [15][16].
  • The “Sick Day” Risk: Common illnesses like a stomach virus (vomiting or diarrhea) can cause your magnesium levels to crash dangerously [17][18]. It is important to have a pre-arranged plan with your doctor for when you cannot keep your supplements down.
  • Advocating for Yourself: Carrying a medical alert card or a letter from your specialist is vital. This letter should not instruct the ER to simply dismiss a dangerously low value; instead, it should contain your confirmed diagnosis, variant, your usual baseline laboratory values, current medicines and supplements, treating-clinician contact information, and an individualized plan stating when urgent assessment or replacement is needed [19].

While the diagnosis may feel isolating, remember that “rare” does not mean “unmanageable.” By building a consistent routine and a knowledgeable care team, you can take control of your long-term health [20][1].

Common questions in this guide

What is the long-term outlook for Glaudemans type hypomagnesemia?
Published experience is limited because this condition is rare, so exact survival and complication risks are not well established. The outlook depends on the specific genetic variant, kidney function, and how well low magnesium and other electrolyte problems are controlled.
How often should my magnesium and other electrolytes be tested?
Some specialists check magnesium, calcium, and potassium about every three to six months, but there is no single schedule for everyone. Your clinician may adjust testing based on symptoms, treatment, kidney function, illness, pregnancy, and changes in your health.
Why might I need an EKG with Glaudemans type hypomagnesemia?
Very low magnesium can delay the heart's electrical reset, which may lengthen the QTc interval and raise the risk of an abnormal rhythm. A baseline and periodic EKG may help your clinician monitor this risk.
What should I do if vomiting or diarrhea keeps me from taking magnesium?
Vomiting and diarrhea can make magnesium levels fall quickly, especially when you cannot keep oral supplements down. Ask your clinician in advance for a sick-day plan that explains when to seek urgent assessment and magnesium replacement.
Does Glaudemans type cause calcium deposits in the kidneys?
Unlike some other inherited magnesium disorders, Glaudemans type is not typically associated with widespread nephrocalcinosis, meaning calcium deposits in the kidneys. Your care team may still monitor kidney function and decide whether an ultrasound is appropriate for your individual history.
Could my KCNA1 variant affect seizures or coordination?
The effect of a KCNA1 variant depends on the specific genetic change and your clinical history. Ask your care team whether a baseline neurological evaluation is appropriate if you have seizures, muscle twitching, or coordination problems such as ataxia.
What information should I carry for emergency care?
Carry a medical alert card or specialist letter with your confirmed diagnosis, genetic variant, usual laboratory values, medicines and supplements, clinician contact details, and individualized instructions for urgent care. The information should guide emergency assessment and replacement decisions rather than tell staff to dismiss a dangerously low magnesium result.

Get notified when new evidence is published on Isolated autosomal dominant hypomagnesemia, Glaudemans type.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (20)
  1. 1

    A de novo KCNA1 Mutation in a Patient with Tetany and Hypomagnesemia.

    van der Wijst J, Konrad M, Verkaart SAJ, et al.

    Nephron 2018; (139(4)):359-366 doi:10.1159/000488954.

    PMID: 29791908
  2. 2

    A case of chronic hypomagnesemia in a cancer survivor.

    Velimirovic M, Ziperstein JC, Fenves AZ

    Hospital practice (1995) 2017; (45(2)):58-64 doi:10.1080/21548331.2017.1286924.

    PMID: 28114816
  3. 3

    SUDEP risk and autonomic dysfunction in genetic epilepsies.

    Sahly AN, Shevell M, Sadleir LG, Myers KA

    Autonomic neuroscience : basic & clinical 2022; (237()):102907 doi:10.1016/j.autneu.2021.102907.

    PMID: 34773737
  4. 4

    Distal renal tubular acidosis: ERKNet/ESPN clinical practice points.

    Trepiccione F, Walsh SB, Ariceta G, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2021; (36(9)):1585-1596 doi:10.1093/ndt/gfab171.

    PMID: 33914889
  5. 5

    Outcome of primary tubular tubulopathies diagnosed in pediatric age.

    Gómez CJB, Gil-Peña H, Álvarez FAO, Rodríguez FS

    Nefrologia 2021; (41(2)):182-190 doi:10.1016/j.nefroe.2020.07.001.

    PMID: 36165379
  6. 6

    [Management of Gitelman syndrome during pregnancy reporting 12 cases].

    Elbouajaji K, Blanchier D, Pourrat O, Sarreau M

    Nephrologie & therapeutique 2018; (14(7)):536-543 doi:10.1016/j.nephro.2018.06.003.

    PMID: 30309814
  7. 7

    Vonoprazan-associated hypomagnesemia presenting to the emergency department with altered mental status and a suspected seizure.

    Okamoto N, Onishi S, Manabe T, et al.

    The American journal of emergency medicine 2026; (101()):131-134 doi:10.1016/j.ajem.2025.12.034.

    PMID: 41512442
  8. 8

    Hypomagnesemia and hypermagnesemia.

    Van Laecke S

    Acta clinica Belgica 2019; (74(1)):41-47 doi:10.1080/17843286.2018.1516173.

    PMID: 30220246
  9. 9

    Therapeutic Potential of Sodium Channel Blockers as a Targeted Therapy Approach in KCNA1-Associated Episodic Ataxia and a Comprehensive Review of the Literature.

    Lauxmann S, Sonnenberg L, Koch NA, et al.

    Frontiers in neurology 2021; (12()):703970 doi:10.3389/fneur.2021.703970.

    PMID: 34566847
  10. 10

    New insights into the pathogenesis and therapeutics of episodic ataxia type 1.

    D'Adamo MC, Hasan S, Guglielmi L, et al.

    Frontiers in cellular neuroscience 2015; (9()):317 doi:10.3389/fncel.2015.00317.

    PMID: 26347608
  11. 11

    Episodic Ataxia Type 1: Natural History and Effect on Quality of Life.

    Graves TD, Griggs RC, Bundy BN, et al.

    Cerebellum (London, England) 2023; (22(4)):578-586 doi:10.1007/s12311-021-01360-6.

    PMID: 35655106
  12. 12

    Clinical Characteristics, Symptoms, and Long-Term Outcomes in Gitelman Syndrome.

    Wieërs MLAJ, Allard L, D'Ambrosio V, et al.

    Kidney international reports 2025; (10(11)):3967-3983 doi:10.1016/j.ekir.2025.09.006.

    PMID: 41278357
  13. 13

    Two novel KCNA1 variants identified in two unrelated Chinese families affected by episodic ataxia type 1 and neurodevelopmental disorders.

    Yuan H, Yuan H, Wang Q, et al.

    Molecular genetics & genomic medicine 2020; (8(10)):e1434 doi:10.1002/mgg3.1434.

    PMID: 32705822
  14. 14

    Musculoskeletal Features without Ataxia Associated with a Novel de novo Mutation in KCNA1 Impairing the Voltage Sensitivity of Kv1.1 Channel.

    Imbrici P, Accogli A, Blunck R, et al.

    Biomedicines 2021; (9(1)) doi:10.3390/biomedicines9010075.

    PMID: 33466780
  15. 15

    QT interval prolongation associated with low magnesium in chronic alcoholics.

    Moulin SR, Mill JG, Rosa WC, et al.

    Drug and alcohol dependence 2015; (155()):195-201.

    PMID: 26249264
  16. 16

    Multiple dyselectrolytemia in a patient with alcohol use disorder (AUD).

    Abe E, Kawai Y, Sato M, et al.

    CEN case reports 2026; (15(2)):53 doi:10.1007/s13730-025-01054-6.

    PMID: 41692905
  17. 17

    Dysmagnesemia in critically ill diarrheal patients in Bangladesh.

    Alam A, Mamun GMS, Sarmin M, et al.

    PloS one 2025; (20(5)):e0323467 doi:10.1371/journal.pone.0323467.

    PMID: 40388464
  18. 18

    Profound Hypomagnesemia Due to Proton Pump Inhibitor Use-Associated Wernicke's Encephalopathy: A Case Report on Excitotoxicity.

    Delforge B, Volon B, Laurent Y, Steinier C

    Cureus 2025; (17(10)):e94687 doi:10.7759/cureus.94687.

    PMID: 41246742
  19. 19

    Home Parenteral Support in Severe Gitelman Syndrome: A Case Report.

    Martin G, Fahal I, Mehta S

    Clinical case reports 2026; (14(7)):e73210 doi:10.1002/ccr3.73210.

    PMID: 42487655
  20. 20

    The challenges of diagnosis and management of Gitelman syndrome.

    Urwin S, Willows J, Sayer JA

    Clinical endocrinology 2020; (92(1)):3-10 doi:10.1111/cen.14104.

    PMID: 31578736

This page is for informational purposes only and does not constitute medical advice about Glaudemans type hypomagnesemia. Your nephrologist and other treating clinicians should individualize monitoring, supplements, sick-day plans, and urgent-care instructions for your situation.

Guide contents Isolated autosomal dominant hypomagnesemia, Glaudemans type
Research & Literature
05 Building Your Rare Disease Care Team